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Abstract
Glioblastoma is a common brain malignancy that tends to occur in older adults and
is almost always lethal. The effectiveness of chemotherapy, being the standard treatment
for most cancer types, can be improved if a particular genetic sequence in the tumor
known as MGMT promoter is methylated. However, to identify the state of the MGMT
promoter, the conventional approach is to perform a biopsy for genetic analysis, which is
time and effort consuming. A couple of recent publications proposed a connection between
the MGMT promoter state and the MRI scans of the tumor and hence suggested the use
of deep learning models for this purpose. Therefore, in this work, we use one of the most
extensive datasets, BraTS 2021, to study the potency of employing deep learning solutions,
including 2D and 3D CNN models and vision transformers. After conducting a thorough
analysis of the models’ performance, we concluded that there seems to be no connection
between the MRI scans and the state of the MGMT promoter.
Keywords: Radiogenomics, Glioblastoma, MGMT promoter, Deep learning

1. Introduction
Glioblastoma multiforme is the most malignant and aggressive brain tumor, constituting
60% of adult brain tumors (Taylor et al., 2019). O6 -Methylguanine-DNA methyltransferase
(MGMT) is a DNA repair enzyme that reduces the effects of alkylating chemotherapeutic
agents on tumor cells, leading to a poor response to temozolomide (Taylor et al., 2019).
MGMT promoter methylation, or MGMT gene silencing, is a key prognostic factor in
predicting the patient’s chemotherapy response. Since temozolomide increases the patient’s
survival rate, the methylation status could contribute to clinical decision (Weller et al.,
2010). Patients whose MGMT promoter is methylated report a median survival rate of
21.7, compared to 12.7 months for patients with unmethylated MGMT. The information
concerning molecular and genetic alterations of gliomas is usually obtained via invasive
procedures, such as biopsy or open surgical resection.
The field of radiomics aims to analyze the relationship between clinical diagnoses and
genetic characteristics. Identification of genetic properties of tumors could be more effective
in creating a personalized treatment plan for each patient (Riemenschneider et al., 2010).
Radiomics derives features from medical images to quantify the brain tumor phenotype.
Thus, novel non-invasive approaches are being proposed in order to predict the methylation
status from magnetic resonance images (MRI).
© N. Saeed, S. Hardan, K. Abutalip & M. Yaqub.
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There are several studies that showcased the ability of predicting the MGMT promoter
status through deep-learning solutions (Chang et al., 2018; Yogananda et al., 2020; Chang
et al., 2018). However, many other clinical and machine learning-based studies showed a
contradicting result and argued there is no direct relationship between the MGMT promoter
state and the MRI scans (Han and Kamdar, 2018; Egaña et al., 2020; Mikkelsen et al., 2020).
In this study, we investigate the ability of state-of-the-art machine learning models to
classify the MGMT promoter methylation status. First, we pre-process the MRI scans and
then use them to implement three different approaches: applying 2D and 3D convolutional
neural networks (CNN), a self-supervised learning (SSL) technique, and vision transformers
(ViT). Then, we follow our implementation results with a discussion on the efficacy of these
models to predict the MGMT promoter methylation status.

2. Related Work
Many attempts involving deep learning methods have recently reported appealing results
in classifying MGMT promoter methylation status. Authors in (Chang et al., 2018) have
trained a CNN with residual connections to classify the methylation status using T2, FLAIR,
T1-weighted pre-and postcontrast MRI scans and achieved a mean accuracy score of 83%
on 5-fold cross-validation. MRIs of either low or high-grade gliomas and their corresponding
genetic information were obtained from The Cancer Imaging Archives (TCIA) (Clark et al.,
2013) and The Cancer Genome Atlas (TCGA) (Tomczak et al., 2015). In another work by
(Yogananda et al., 2020), they introduced an MGMT-net, T2WI-only network based on
3D-Dense-UNets, for determining MGMT methylation status alongside segmenting tumors.
They report a mean cross-validation accuracy of 94.73% across 3 folds with sensitivity and
specificity scores of 96.31% and 91.66%, respectively. The data were from TCIA and TCGA
databases. Similar to (Chang et al., 2018), but by using full T2 images performed at Mayo
Clinic with recorded MGMT methylation information, Korfiatis et. al. (Korfiatis et al.,
2017) used ResNet50 and demonstrated an accuracy of 94.90% on a test set.
Despite the success of conventional CNNs in the discussed context above, recent studies
raise some concerns regarding MGMT methylation’s predictive value and the feasibility of
solving this problem using deep learning techniques. Han et. al. (Han and Kamdar, 2018)
have used a recurrent CNN model that produced a test accuracy of 62% with precision and
recall of 0.67. In the Brain Tumor Radiogenomic Classification challenge (Baid et al., 2021;
Menze et al., 2015; Bakas et al., 2017), which was hosted by the Radiological Society of
North America (RSNA) and the Medical Image Computing and Computer-Assisted Interventions (MICCAI) conference, participants were not able to achieve more than 0.62 AUC
score, even though the most extensive dataset for this task was provided. In a recent clinical
study (Egaña et al., 2020), epigenetic silencing of MGMT promoter did not help predict
response to TMZ in a cohort of 334 patients diagnosed with glioblastoma or high-grade
glioma. The study indicates no relationship between methylation of MGMT promoters and
overall survival rates. The authors in (Mikkelsen et al., 2020) investigated from a clinical
perspective the associations between this predictive biomarker and several radiological and
histopathological features in patients with dehydrogenase (IDH) wild-type glioblastomas.
There were no associations between investigated features, including MRI scans character2
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Figure 1: A sample of four random slices from different MRI modalities.
istics, overall survival, and MGMT status. Authors suggest that the methylation status of
MGMT cannot be non-invasively predicted from MRI features.

3. Dataset
The dataset used in this study is from the Brain Tumor Radiogenomic Classification challenge (Baid et al., 2021) that includes multi-parametric MRI (mpMRI) scans for 585 glioblastoma patients having 348,641 scans. It was split to 80% training data and 20% testing
data. Patients with IDs [00109, 00123, 00709] were removed from the dataset due to issues present in their images. The patients belong to two classes: methylated MGMT and
unmethylated MGMT. The dataset is balanced, containing 307 methylated cases and 278
unmethylated cases. Images are in DICOM format that comes with an associated header
including clinical information such as modality, orientation, and MRI machine-specific details. Each patient has images in four different modalities: T1-weighted pre-contrast (T1),
T1-weighted post-contrast (T1Gd (Gadolinium)), T2-weighted (T2), and T2 Fluid Attenuated Inversion Recovery (T2-FLAIR). The number of slices for each patient differ. MRI
images come in three orientations, including coronal, axial, and sagittal. In all the experiments in this manuscript, we use FLAIR or T1wCE type images as the tumor appears
bright and easier to distinguish; tumor is thought to encode the information concerning the
MGMT promoter state. Figure 1 shows four random slices displaying the four modalities
and the existence of different orientations for the same patient. The brain images provided
are already pre-processed by being co-registered to the same anatomical template (SRI24),
resampled to a uniform isotropic resolution, and skull stripped. The Brain Tumor Radiogenomic Classification challenge dataset includes images from various collections such as
the TCIA (Clark et al., 2013) public collection of TCGA-GBM, ACRIN-FMISO-Brain collection (ACRIN 6684)(Gerstner et al., 2016; Kinahan et al., 2018), and other public and
private datasets. The following preprocessing steps were performed in this study for all the
experiments: 1) Resampling the scans to the axial plane for consistency. 2) For 3D experiments, extracting the same number of slices for each patient. If any further preprocessing
steps were performed for an experiment, they would be mentioned in the relevant sections.

3
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4. Experiments
4.1. Are 2D and 3D CNNs capable of predicting the MGMT promoter status?
CNNs have proven to be effective in various medical imaging applications, including classification. In the first experiment, variations of 2D CNN architecture based on deep residual
learning network (ResNet) (He et al., 2015) with 18, 34, 50 layers, and dense connections
(DenseNet) (Huang et al., 2018) with 121, 161 layers were used to train the models. Such
networks allow to train deeper models without accuracy degradation and address the issue
of vanishing gradients. For the 3D CNN model experiment, we implemented 3D EfficientNet to utilize its ability to capture the information along the depth dimension of the MRI
scans. Furthermore, an ensemble network was designed to combine FLAIR and T1wCE
modalities: inputs were passed through two branches of the network (ResNet18 without
fully connected (FC) layers), and feature maps were either stacked or added before the FC
layer. The figure and other details about this experiment can be found in Appendix A. The
MRI scans were further preprocessed: 1) cropping the brain part, 2) resizing to three image
resolutions for different experiments: 128 × 128, 256 × 156, 512 × 512, 3) 3D contrast limited
adaptive histogram equalization (Amorim et al., 2018). In 2D CNN-based classification,
additional filtration steps were performed to exclude slices without the tumor.
The last few experiments with CNN models were focused on the region of interest (ROI)
- based classification. Segmentation masks for 574 patients were provided in Task 1 of The
RSNA-ASNR-MICCAI BraTS 2021 challenge (Baid et al., 2021). Slices were selected based
on the segmentation masks to extract only the tumor region, which was resized to image
resolutions of 128 × 128 and 32 × 32. The small image size was used to examine the
same approach described in (Chang et al., 2018). The authors used 32 × 32 × 4 input
resolution, where four corresponds to stacking different MR modalities, to train custom
ResNet comprised of four residual blocks with additional minor modifications. For further
details, see Appendix A.
For an extensive evaluation of the networks mentioned above, hyperparameters were
tweaked in the following way: the number of epochs varied from 15 to 30, weight decay
was set to 0.01 or was not used. For random initializations, the seed was not fixed. Adam
optimizer and step-based learning rate scheduling were used. Settings for other hyperparameters and results of the main experiments can be found in Table 1. Overall, selected
models either strongly exhibited overfitting behavior or could not capture the relationship
between MRI features and MGMT promoter status. It was observed that the training loss
fluctuated around the value of 0.7. The rest of the experiments are available in Appendix
A. Possible reasons might include noise in the data and insufficient model complexity. More
sophisticated network architectures were considered in the following sections.
4.2. Can self-supervision benefit the CNNs in prediction?
Due to the scarcity of labeled images in the medical field (Azizi et al., 2021), SSL methods
are used to leverage the large number of unlabeled datasets. In this experiment, we use
SimCLR (Chen et al., 2020), a contrastive-based SSL algorithm, to pre-train a ResNet18
model with a proxy task and then finetune it on the downstream task dataset. BraTS 2020
dataset (Menze et al., 2015) was used for the proxy task in the pretraining stage. The
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Table 1: Results of the main experiments with CNNs. Pret: (Pretrained where 0 and 1 are
for Random and ImageNet weights model initialization), Aug: Augmentations. ∗ - as two
channels, LR: Learning rate, BS: Batch size.
Model
ResNet34
ResNet50
DenseNet121
3D-EfficientNet
Custom ResNet
ROI Custom ResNet

Pret.

Modality

Img Res.

Aug.

LR

BS

0
1
1
0
1
0

FLAIR
FLAIR
FLAIR
FLAIR
Stacking
Combined∗

256
128
128
256
128
32

Yes
Yes
Yes
No
Yes
No

1e-2
1e-2
1e-2
1e-3
1e-3
1e-2

128
128
128
4
128
16

Train
AUC
0.83
0.61
0.63
0.76
0.70

Val.
AUC
0.54
0.58
0.58
0.64
0.63
0.53

BraTS 2020 dataset includes MRI scans of four modalities belonging to 369 patients. The
modalities T1, T1w, T2w, and FLAIR, were all included in the proxy task data to maximize
the model’s understanding of the variations in brain MRI. We extracted 80,720 slices and
resized them to 128×128, disregarding those containing an inconsiderable view of the brain.
The pretraining task used a learning rate of 0.1, batch size of 256, and the SGD optimizer
with a momentum of 0.9. The augmentations applied are random vertical and horizontal
flips, random rotations, and random Gaussian smoothing.
We took 20 slices from each patient for the downstream task and used them as a 20
channel 2D input to the model. The 20 images are of the type FLAIR, in the axial orientation, and resized to 128 × 128. They were chosen by taking the slice containing the
maximum cutaway of the brain as the central slice. The augmentations implemented on the
downstream task are random affine transforms, random Gibbs noise, and random Gaussian
smoothing. The batch size used was 16, the learning rate was 0.001, and the optimizer was
AdamW. These parameters were experimentally chosen. The validation AUC was fluctuating around 0.6, and the validation loss around 0.7. The final trained model behavior shows
that employing SimCLR to pretrain the model did not lead to significant improvement.
Appendix B presents how the SimCLR model works and the learning curves for the final
downstream experiment.
4.3. Is Vision Transformer’s attention mechanism capable of predicting the
methylation status?
Recently, Dosovitskiy et. al. (Dosovitskiy et al., 2020) proposed Vision Transformers (ViTs)
to perform tasks such as image classification. ViT is a concept adapted from transformers in
the NLP domain. ViTs uniqueness comes from the attention mechanism it employs, which
is utilized to capture long-range relationships and provide insight into what the model is
focused on. Hence, in this experiment we employed ViTs to predict the methylation status.
OPTUNA framework (Akiba et al., 2019) was used to optimize the hyperparameters of the
ViT model. A batch size of 16, a learning rate of 0.007 and Adam optimizer were found as
the best combination of hyperparameters. A summary of the rest of the hyperparameters
are listed in Appendix C.
As for the differences in the number of slices across patients, we chose the slice that
shows the maximum cutaway of the brain as the central slice with 32 additional slices on
5
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Figure 2: Histogram and Kernel Density Estimation (KDE) of predicted classification probabilities of three ViT models trained with different seeds.
each side. The MRI scans were resized to 256 × 256 × 64. The validation AUC was found
to be 0.58.
Since simple and complex models resulted in a validation accuracy no more than 0.6, the
ViT model was trained with random seeds. Figure 2 shows the distribution of predictions
for three of these models. As can be observed, the distribution of prediction on test set is
far from being bi-modal which suggests discrimination between the two classes is very poor.
The same experiment was conducted for an additional six ViT models with different seeds,
a similar pattern of prediction is observed (Appendix C).

5. Discussion
The accuracy of all the models attempted during this study was very low. Hence, the
focus was to understand the performance of these models and the models that won the
RSNA-MICCAI competition. The following experiment, along with the remainder of the
experiments in this manuscript, was based on ResNet10 model. The choice of this model
is motivated by the winning solution of the Kaggle competition and due to its simplicity,
which makes it ideal for exploring multiple experiments.

Figure 3: Histogram of the predicted classification probabilities conditioned on true labels
for three different experiments.
It was found that the top three models in the competition, when used for inference
on the test set, show a similar uni-modal distribution as discussed in the previous section.
Unfortunately, the test labels for this dataset are not available publicly. Hence, part of
the training data was reserved as a validation set while ensuring stratified sampling in the
training and the validation sets as per Table 2. The model was trained using ten different
6
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Table 2: Class distribution of train- Table 3: The performance of 5 randomly
ing set
selected ResNet10 models
Class
0
1

Training
222
246

Validation
56
61

Model
AUC

1
0.57

2
0.59

3
0.54

4
0.58

5
0.57

random seeds and then tested on the validation set. The validation accuracy of five of
these models is listed in Table 3, and the rest of the validation AUC are in Appendix C.
It is evident that the performance of all ten models is slightly better than a random guess.
Figure 3 shows the prediction distribution of three of these models colored based on the
true labels. The figure shows a significant overlap in the prediction distribution, suggesting
that the model’s prediction is primarily random. In addition, the mean of prediction varies
significantly with the change of the seed. This behavior can be visually illustrated in
Figure 5, which shows that all these models perform equally random because they cannot
differentiate between the two classes. Additionally, this behavior indicates that the models
are learning irrelevant noise and are incapable of finding predictive features.
To confirm the above hypothesis, the training loss curves for our models were observed.
The training loss is initially high and saturates to an average value of 0.7 towards the end
of the training, as shown in Figure 4. This trend was observed in our models and many
other models on Kaggle. To explain this behavior, the binary cross entropy (BCE) loss
Equation (1) is solved under the assumption that both classes are almost equally represented
in the training set, and the model is in a random state, i.e., predicting both class 0 and 1
with probability 0.5. Solving Equation (1) yields a loss of 0.69, which explains that these
models are in random states even after 15 epochs.
N
1 X
Loss = −
yi × log(p(yi )) + (1 − yi ) × log(1 − p(yi ))
N

(1)

i=1

Figure 4: Training loss curves for different Figure 5: Class overlap with random splits
models.
representing decision boundaries
‘
7
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5.1. Interpretability
To interpret the trained ResNet10 model, the feature maps of a batch size of 128 were
extracted at each layer, as shown in Appendix C. It was challenging to interpret the feature
maps; therefore, we used t-SNE (Van der Maaten and Hinton, 2008) to plot them at every
layer in a 2D space. It can be observed that towards the final layers, the two classes are
still entangled, suggesting that the model is unable to find features that will differentiate
between the two classes, as can be observed from Figure 6. As shown in Appendix C, the
feature maps were extracted from the same model trained on MNIST-10. It is clear that
the model can learn predictive features and can separate between the ten classes towards
the final layers of the model. This experiment also confirms the hypothesis that there is no
difference between the features extracted from the two classes’ data.

Figure 6: Feature visualization via t-SNE. The diffused points show that the model is not
able to separate the two classes.

6. Conclusion
Finally, to answer the question posed in the title: although they showed promising performance in many medical applications, we believe that the current deep learning models
cannot predict MGMT Promoter state using only patient MRI scans. As in this holistic
study, we conducted a large number of experiments with different deep-learning architectures, but they all yielded an AUC that is not significantly better than a random guess for a
binary classification problem. Models with this kind of performance cannot be used in clinical settings, and hence, as we stand, there is no alternative to surgical biopsies. However,
other biomarkers may exist that the deep learning model could use for better prediction.
The future effort shall be focused on finding these biomarkers.
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Appendix A. Supplementary Details for CNN Methods
Table 4 shows the results for extended list of experiments.
Table 4: Results of the main experiments with 2D CNNs. Initialization: 0: Random, 1:
ImageNet weights, Aug:Augmentations. ∗ - as two channels.
Model
ResNet34
ResNet34
ResNet34
Resnet34
ResNet50
DenseNet121
DenseNet161
Custom ResNet
Custom ResNet
ROI ResNet18
ROI ResNet18 + more FC
ROI Custom ResNet

Init.

Modality

Img Res.

Aug.

0
0
1
1
1
1
1
1
0
0
1
0

FLAIR
FLAIR
T1wCE
T1wCE
FLAIR
FLAIR
T1wCE
Stacking
Addition
FLAIR
T1wCE
Combined∗

128
256
128
256
128
128
128
128
128
128
128
32

No
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
No
Yes
No

Train
AUC
0.95
0.83
0.51
0.99
0.61
0.63
0.51
0.76
0.50
0.97
0.88
0.70

Val.
AUC
0.51
0.54
0.55
0.52
0.58
0.58
0.50
0.63
0.49
0.55
0.55
0.53

Architectural design of the model for ROI-based classification can be found in Figure 7.

Figure 7: Architecture of the custom ResNet for ROI-based classification, as described
in (Chang et al., 2018). Each residual block is comprised of two convolutional blocks
with added dropout layer. After each stage, feature maps are downsampled by applying
convolution with stride 2 (indicated by /2). 4 × 4 Average pooling is used before FC layer.
Figure 8 depicts the architecture of the custom ensemble network for utilizing information from two MRI modalities.
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Figure 8: Architecture of the custom ResNet for combining FLAIR and T1wCE modalities.

Appendix B. Supplementary Details for Self-Supervised Learning
Methods
Figure 9 shows the SimCLR self-supervision procedure in the proxy task. In Figure 10,
the learning curves of the downstream task of SimCLR are presented. Both stages use the
ResNet-18 model.

Figure 9: How SimCLR works: Two augmented versions of the same image are taken by the
model and passed to the encoder (ResNet-18). Then, the representations of the encoder are
passed to a non-linear projection head. The goal of SimCLR is to maximize the similarity
of the vectors resulted from the projection head using a contrastive loss. The downstream
task uses the representations from the encoder.

Appendix C. Supplementary Details for Vision Transformer Methods
Table 5 shows the hyperparameter values for the experiments with ViT. These values were
found after running multiple experiments using OPTUNA framework (Akiba et al., 2019).
Figure 11 shows the prediction distribution for different ViT models.
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Figure 10: Learning curves for the SimCLR downstream task.
Table 5: ViT hyperparameter values

Hyperparameter
Batch size
Learning rate
Patch size
Embedding dimension
Model depth
Multi-heads
Head dimension
MLP dimension

Value
16
0.007
32
2048
2
8
1024
512

Appendix D. Supplementary Details for Discussion and Conclusion
Figure 12 shows the predicted probabilities distribution for nine ResNet10 models which
were trained using different random seeds. Figure 13 shows the feature maps extracted at
each layer of ResNet10, when inferred using an MRI scan of a patient. Figure 14 shows the
feature maps of MNIST data extracted at each layer of ResNet10 and projected onto a two
dimensional space using t-SNE. The model is able to perfectly separate the features for the
different class compared to the MRI scans dataset.
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Figure 11: Histogram and Kernel Density Estimation (KDE) of predicted classification
probabilities for ViT models trained with different seeds

Figure 12: Histogram of predicted classification probabilities of ResNet10 models conditioned on true labels

14

MGMT Promoter Methylation

Figure 13: Feature visualization at different layers

Figure 14: Feature visualization via t-SNE for MNIST data
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